shutterstock_2163578799_halawi

Halawi / Shutterstock.com

23 March 2023Big PharmaLiz Hockley

US refuses to compel lower prices for Pfizer and Astellas cancer drug

NIH rejects petition to use “march-in” rights to allow cheaper competition | Xtandi is “widely available” to public, federal agency says.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Actavis hit with IP suit over prostate cancer drug

6 December 2016 Astellas Pharma, Medivation and the regents of the University of California have collectively sued Actavis for alleged patent infringement over Xtandi, a treatment for prostate cancer.

NIH chooses not to use ‘march-in rights’ in prostate drug row

21 June 2016 The US National Institutes of Health has decided not to exercise its “march in-rights” for the Xtandi prostate drug, which is marketed by Astellas Pharma, despite calls from politicians to license the drug in a bid to lower its price.

More on this story

Actavis hit with IP suit over prostate cancer drug

6 December 2016 Astellas Pharma, Medivation and the regents of the University of California have collectively sued Actavis for alleged patent infringement over Xtandi, a treatment for prostate cancer.

NIH chooses not to use ‘march-in rights’ in prostate drug row

21 June 2016 The US National Institutes of Health has decided not to exercise its “march in-rights” for the Xtandi prostate drug, which is marketed by Astellas Pharma, despite calls from politicians to license the drug in a bid to lower its price.

More on this story

Actavis hit with IP suit over prostate cancer drug

6 December 2016 Astellas Pharma, Medivation and the regents of the University of California have collectively sued Actavis for alleged patent infringement over Xtandi, a treatment for prostate cancer.

NIH chooses not to use ‘march-in rights’ in prostate drug row

21 June 2016 The US National Institutes of Health has decided not to exercise its “march in-rights” for the Xtandi prostate drug, which is marketed by Astellas Pharma, despite calls from politicians to license the drug in a bid to lower its price.

More features

Life sciences leaders recognised at LSPN Awards USA 2025

UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body

LSPN: Counsel grapple with AI’s impact on training and critical thinking

'Nothing can stand in the way of our work': Ukraine resumes IP system

LSPN: Trump's policy storm causing chaos and confusion

Taylor Wessing expands in Europe with Paris team

LSPN: Using ‘the patentee’s friend’ in Section 112 claims

ResMed voids sleep apnoea tech patent at PTAB